title: Tavaborole - a treatment for onychomycosis of the toenails.
abstract: BACKGROUND
  Onychomycosis is a fungal nail infection that accounts for half of all nail diseases. Oral drugs on the market have adverse effects, while it is difficult for traditional topical drugs to penetrate the nail plate to reach the diseased nail bed. Tavaborole is a new drug that addresses the unmet needs of currently available treatments. Tavaborole (5%) is FDA approved for treating toenail onychomycosis and has shown antifungal activities against yeast, moulds and dermatophytes.
  
  
  METHODS
  The objective of this article is to review the efficacy, pharmacokinetics, pharmacodynamics, and safety of tavaborole for treatment of toenail onychomycosis. Expert commentary: Tavaborole, with its unique mechanism, may be a good candidate for use in treating children with fungal infections, diabetic individuals, and treating mixed infections. Tavaborole may be paired with other therapies to potentially increase cure rates.
authors.affiliation: a Department of Medicine , University of Toronto School of Medicine , Toronto , ON , Canada.|b Mediprobe Research Inc ., London , ON , Canada.
authors.forename: Aditya K
authors.initials: AK
authors.lastname: Gupta
authors.affiliation: b Mediprobe Research Inc ., London , ON , Canada.
authors.forename: Sarah G
authors.initials: SG
authors.lastname: Versteeg
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001896:Boron Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D005533:Foot Dermatoses / Q000188:drug therapy; D006801:Humans; D014009:Onychomycosis / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; D001896:Boron Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; C512998:tavaborole
keywords: Onychomycosis; fungal infection fungal protein inhibitor; tavaborole; tinea unguium; topical treatment